



www.bioinformatics.net
Volume 20(9)



Research Article

Received September 1, 2024; Revised September 30, 2024; Accepted September 30, 2024, Published September 30, 2024

DOI: 10.6026/973206300200966

BIOINFORMATION 2022 Impact Factor (2023 release) is 1.9.

Declaration on Publication Ethics:

The author's state that they adhere with COPE guidelines on publishing ethics as described elsewhere at <https://publicationethics.org/>. The authors also undertake that they are not associated with any other third party (governmental or non-governmental agencies) linking with any form of unethical issues connecting to this publication. The authors also declare that they are not withholding any information that is misleading to the publisher in regard to this article.

Declaration on official E-mail:

The corresponding author declares that lifetime official e-mail from their institution is not available for all authors

License statement:

This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License

Comments from readers:

Articles published in BIOINFORMATION are open for relevant post publication comments and criticisms, which will be published immediately linking to the original article without open access charges. Comments should be concise, coherent and critical in less than 1000 words.

Disclaimer:

The views and opinions expressed are those of the author(s) and do not reflect the views or opinions of Bioinformatics and (or) its publisher Biomedical Informatics. Biomedical Informatics remains neutral and allows authors to specify their address and affiliation details including territory where required. Bioinformatics provides a platform for scholarly communication of data and information to create knowledge in the Biological/Biomedical domain.

Edited by P Kanguane

Citation: Khattabi *et al.* Bioinformatics 20(9): 966-973 (2024)

Molecular docking and dynamics analysis of flavonoids from *Retama monosperma* with drug-resistant GIST mutations

Kaoutar El Khattabi^{1,*}, Jihane Akachar¹, Sanaa Lemriss², Rachid El Jaoudi¹ & Fouad Zouaidia^{1,3}

¹Medical Biotechnology Laboratory, Rabat Medical and Pharmacy School, Mohammed V University in Rabat, Rabat, Morocco;

²Department of Biosecurity PCL3, Laboratory of Research and Medical Analysis of the Fraternal of Gendarmerie Royale, Rabat, Morocco; ³Pathology Department, Ibn Sina University Hospital, Rabat, Morocco; *Corresponding author

Affiliation URL:

<http://fmp.um5.ac.ma/>

Author contacts:

Kaoutar El khattabi - E-mail: kaoutar_elkhattabi3@um5.ac.ma

Jihane Akachar - E-mail: jihane.akachar@gmail.com

Sanaa Lemriss - E-mail: slemriss@lram-fgr.ma

Rachid El Jaoudi - E-mail: eljaoudi_rachid@yahoo.fr

Fouad Zouaidia - E-mail: zouaidiopathology@gmail.com

Abstract:

Gastrointestinal stromal tumors (GISTs), the most prevalent mesenchymal tumors of the gastrointestinal tract, are predominantly driven by activating mutations in receptor tyrosine kinases such as c-Kit and PDGFR α . Resistance to tyrosine kinase inhibitors (TKIs) poses a substantial therapeutic challenge, underscoring the need for novel treatments. Consequently, investigating the potential of natural compounds, specifically flavonoids from *Retama monosperma*, known for their diverse bioactivities, is of significant interest. Molecular docking and simulations revealed that Luteolin exhibited high binding affinities for PDGFR α (-8.1 kcal/mol) and c-KIT (-9.6 kcal/mol), comparable to Avapritinib and Sunitinib. The compound demonstrated favorable ADMET properties and formed notable hydrogen bonds and hydrophobic interactions with key residues in both targets. Molecular dynamic simulation over 100 ns revealed stable complexes with consistent RMSD and RMSF values. Additionally, Luteolin showed strong binding affinities to the resistant mutations c-Kit (D816H) and PDGFR α (T674I), with enhanced stability. These findings suggest that Luteolin has significant potential as a dual inhibitor and offers a promising alternative to conventional TKIs for addressing GIST resistance.

Keywords: Gastrointestinal stromal tumors, *Retama monosperma*, flavonoids, molecular docking, molecular dynamics simulations.

Background:

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract, originating from the interstitial cells of Cajal or related stem cells [1]. These tumors are driven primarily by activating mutations in the receptor tyrosine kinases c-Kit (KIT) and platelet-derived growth factor receptor alpha (PDGFR α) [2]. Mutations such as c-Kit D816H and PDGFR α T674I lead to constitutive kinase activation, resulting in uncontrolled cell proliferation and resistance to apoptosis, presenting a significant therapeutic challenge [3]. Tyrosine kinase inhibitors (TKIs) like Imatinib have been the cornerstone of GIST treatment; however, resistance to these drugs, often due to secondary mutations, limits their long-term efficacy [4]. Despite developing second-line TKIs such as Sunitinib and Regorafenib, resistance remains a critical issue, necessitating the search for new therapeutic strategies [5]. Natural compounds from medicinal plants have shown promise as alternative or complementary therapies in cancer treatment due to their diverse bioactivities and favorable safety profiles [6]. *Retama monosperma*, a perennial shrub native to the Mediterranean region, has been traditionally used for its medicinal properties, including anti-inflammatory, antimicrobial, and antioxidant effects [7]. Recent research has identified *Retama monosperma* as a source of bioactive compounds, particularly flavonoids, which exhibit significant pharmacological activities [8]. Flavonoids, a group of polyphenolic compounds found in various fruits, vegetables, and medicinal plants, have been extensively studied for their anti-cancer properties. These compounds have demonstrated the ability to modulate multiple signaling pathways, including those involving receptor tyrosine kinases (RTKs), such as EGFR and VEGFR. By inhibiting these kinases, flavonoids interfere with cancer cell proliferation, survival, and angiogenesis, making them versatile agents in cancer therapy [9]. Among the flavonoids, Luteolin has demonstrated potent anti-cancer effects, including cell proliferation inhibition, apoptosis induction, and angiogenesis suppression [10]. Other flavonoids such as Genistein, 6-Hydroxygenistein, and Kaempferol have also shown promise in preclinical studies [11]. The potential of natural compounds in targeting GISTs has been highlighted in several studies. For instance, trichostatin A, a natural histone deacetylase (HDAC) inhibitor, has shown efficacy in treating

GISTs by altering gene expression in cancer cell proliferation and survival [12]. Homoharringtonine (HHT), another natural compound, has been found to effectively reduce KIT protein levels by inhibiting protein translation in GIST cells [13]. Therefore, it is of interest to investigate the potential of these phytochemicals in targeting resistant mutations in c-Kit (D816H) and PDGFR α (T674I) through computational methods [14]. Therefore, it is of interest to develop novel therapeutic strategies against TKI-resistant GISTs, addressing a critical unmet need in oncology.

Material and Methods:**Protein preparation:**

We utilized PDB IDs 8PQH and 3G0F for the PDGFR α and c-KIT crystal structures, respectively, with resolutions of 2.50 Å and 2.60 Å. Sequences were prepared for docking using PyRx software [15].

Definition of the active site and functional residues:

Binding and active sites were defined using the UniProt database for both PDGFR α (ID UniProt: Q9DE49) and c-KIT (ID UniProt: P10721) [16].

Phytochemical library preparation:

The chemical structures of three flavonoids, Luteolin, Genistein, and Kaempferol, were selected from *Retama monosperma*, as identified in the study "A Comprehensive Review of the Pharmacological Properties and Bioactive Components of *Retama monosperma*" [17]. We also added 6-hydroxygenistein (6-OHG), a derivative of Genistein.

Virtual screening:

Docking was performed using PyRx, and hit compounds were classified based on their binding affinity scores. Due to its high score, Luteolin was subjected to further analysis and molecular dynamics simulation [15].

Ligand-receptor interaction analysis:

The Discovery Studio Visualizer examined 2D representations of receptor-ligand interactions. These visualizations included graphs of hydrogen bonding and hydrophobic interactions,

providing insights into the compound affinity within the active sites of both targets [18].

Drug-like properties of phytochemicals:

The drug-like properties of the top-docked phytochemicals were assessed, including predictions on absorption, distribution, metabolism, excretion, and toxicity profiles. These assessments were conducted using SwissADMET [19].

Molecular Dynamics Simulation:

Molecular Dynamics (MD) simulations were conducted using the Desmond module of Schrödinger software, applying the OPLS3e force field [20]. The stability and interactions of Luteolin with mutant forms of c-Kit (D816H) and PDGFR α (T674I) were assessed over 100 ns trajectories to elucidate binding dynamics and conformational stability [21]. The simulations involved solvating the initial structures of c-Kit D816H and PDGFR α T674I docking complexes with Luteolin in an orthorhombic boundary box using the TIP3P water model [22]. System preparation included neutralization with sodium (Na⁺) and chloride (Cl⁻) ions and application of the SHAKE algorithm to maintain bond geometry constraints and, coulomb interactions were calculated with a cut-off radius of 10 Å using the particle mesh Ewald (PME) method [23]. Subsequent MD simulations were conducted for 100 ns, saving trajectories at 4.8 ps intervals. The stability of the complexes was analyzed using root mean square deviation (RMSD) and root mean square fluctuation (RMSF) metrics, complemented by simulation interaction diagrams (SID) in the Desmond MD package [20].

Results & Discussion:

Molecular docking and interaction analysis:

The molecular docking analysis was performed to assess the binding affinities of selected flavonoids—Luteolin, Genistein, Kaempferol, and 6-Hydroxygenistein—against the mutant kinases PDGFR α T674I and c-Kit D816H. Using the PyRx virtual screening program, we determined the binding energies of this compound. We compared them with those of the reference inhibitors Avapritinib and Sunitinib, which are clinically used to treat GISTs. The results revealed that Luteolin exhibited the highest binding affinity among the tested flavonoids. Specifically, Luteolin showed a binding energy of -8.1 kcal/mol for PDGFR α , which, while slightly less favorable than Avapritinib's -10.2 kcal/mol, still indicated a strong interaction potential (Table 1). In contrast, Luteolin demonstrated superior binding affinity for c-Kit, with a binding energy of -9.6 kcal/mol which is more than for sunitinib's -8.2 kcal/mol (Table 2). This suggests that Luteolin may be a more effective inhibitor for c-Kit than the currently used Sunitinib.

Table 1: Docking Results of Bioactive Components from Moroccan *Retama monosperma* Against PDGFR α T674I

Ligand	Binding affinity to PDGFR α
Avapritinib	-10.2 Kcal/mol
6-hydroxygenistein	-7.8 Kcal/mol
Genistein	-7.7 Kcal/mol

Kempferol	-7.9 Kcal/mol
Luteolin	-8.1 Kcal/mol

Table 2: Docking Results of Bioactive Components from Moroccan *Retama monosperma* Against c-Kit D816H

Ligand	Binding Affinity to C-Kit
Sunitinib	-8.2 Kcal/mol
6-hydroxygenistein	-8.8 Kcal/mol
Genistein	-8.6 Kcal/mol
Kempferol	-9.5 Kcal/mol
Luteolin	-9.6 Kcal/mol

The binding modes were further analyzed using Discovery Studio Visualizer, which allowed us to visualize the interactions between Luteolin and the active sites of the mutant kinases (Figures 1 and 2). In the PDGFR α complex, Luteolin's carboxyl group formed two hydrogen bonds with the key residues CYS677 and LYS627 and engaged in Pi-Sigma interactions with LEU599, GLY600, and VAL607. By comparison, Avapritinib, although forming a hydrogen bond with CYS677, displayed fewer overall interactions, emphasizing Luteolin's competitive binding affinity. Similarly, in the c-Kit complex, Luteolin established three hydrogen bonds with residues CYS673, GLU640, and LYS623 and also interacted via Pi-Sigma with VAL603. Sunitinib, in contrast, formed only two hydrogen bonds with CYS673 and GLU671, with fewer additional interactions. These findings underscore the potential of Luteolin as a potent dual inhibitor for PDGFR α and c-Kit, with the ability to establish multiple critical interactions within their active sites.

ADMET prediction:

The drug-like properties of Luteolin and other flavonoids were evaluated using ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) predictions to determine their potential as therapeutic agents. The results (Table 3) showed that Luteolin possesses a favorable ADMET profile, including high solubility and good lead-likeness, which are crucial for drug development. These characteristics suggest that Luteolin binds effectively to its targets and has suitable pharmacokinetic properties, making it a promising candidate for further development as a drug.

Molecular dynamics simulations:

To explore the conformational stability of the complexes Luteolin-c-Kit and Luteolin-PDGFR α , we conducted 100 ns molecular dynamics (MD) simulations using Avapritinib and Sunitinib as references. The simulations provided insights into these complexes' static and dynamic characteristics.

RMSD analysis:

The RMSD trajectory of Luteolin stabilized after five ns, with final values of approximately 3.0 Å for PDGFR α and 2.0 Å for c-Kit. These values were notably more stable than those observed for Avapritinib (3.6 Å for PDGFR α) and similar to those for Sunitinib (2.1 Å for c-Kit) (Figures 3a and 4a). The RMSD fluctuations of Luteolin remained consistent and stable after 7.5 ns, fluctuating within the range of 3.0-3.5 Å, lower than Avapritinib's 3.6-4.2 Å and Sunitinib's.




Figure 1: (A) 2D Interaction Diagram of the Cocystal Inhibitor Avapritinib with Residues of the PDGFR α T674I Mutant; (B) 2D Interaction Diagram of Luteolin with Residues of the PDGFR α T674I Mutant

Table 3: ADMET prediction for the investigated bioactive components of Moroccan *Retama monosperma*

	MW g/mol <350	logP <5	HBD <5	HBA <10	Solubility	GI absorption	Lipinski	Leadlikeness
Avapritinib	522.75	4.26	6	11	Soluble	Low	No	No
Sunitinib	315.43	2.16	5	6	Soluble	High	Yes	Yes
6-Hydroxygenistein	286.24	2.06	4	6	Soluble	High	Yes	Yes
Genistein	270.24	1.91	3	5	Soluble	High	Yes	Yes
Kempferol	286.24	1.7	4	6	Soluble	High	Yes	Yes
Luteolin	300.35	1.49	4	6	Very Soluble	High	Yes	Yes




Figure 2: (A) 2D Interaction Diagram of the Cocystal Inhibitor Sunitinib with Residues of the c-Kit D816H Mutant; (B) 2D Interaction Diagram of Luteolin with Residues of the c-Kit D816H Mutant

RMSF analysis:

Luteolin showed higher RMSF values, indicating greater flexibility within the protein-ligand complex, compared to Avapritinib and Sunitinib, which exhibited lower RMSF values, signifying more restricted movement (Figures 3b and 4b). This flexibility may provide an advantage in dynamic biological environments.

Hydrogen bonding and protein-ligand contacts:

Luteolin established a maximum of 8 hydrogen bonds in the PDGFR α complex and an average of 3 hydrogen bonds in the c-Kit complex, exceeding the hydrogen bonds formed by Avapritinib (1) and Sunitinib (3) (Figures 3c and 4c). Key residues involved in these interactions included ARG587, LYS627, GLU675, TYR676, CYS677, PHE678, ASP681, and ASP836 in PDGFR α , and LEU595, LYS623, CYS673, ASP677, and ASP810 in c-Kit.

Interaction tendencies during simulation:

The tendency of specific residues to interact with Luteolin throughout the simulation was monitored, with CYS677 and PHE687 in PDGFR α , and CYS673, ASP810, LYS623, GLU640, TYR672, and ASP677 in c-Kit, showing the strongest binding propensity. These residues were involved in interactions for 96% of the total simulation frames, demonstrating Luteolin's consistent and stable interaction with these key residues (Figures 3d and 4d).

Conclusion:

This study highlights Luteolin's potential as a dual inhibitor of PDGFR α T674I and c-Kit D816H, mutations associated with drug resistance in gastrointestinal stromal tumors (GISTs). The comprehensive analysis, encompassing molecular docking, ADMET predictions, and molecular dynamics simulations, demonstrates Luteolin's superior binding affinity and stability compared to conventional inhibitors like Avapritinib and

Sunitinib. Luteolin's ability to maintain strong and flexible binding interactions in the dynamic environment of the active sites further supports its candidacy for therapeutic development. Future research should focus on validating these computational findings through experimental studies to realize Luteolin's therapeutic potential fully.

Data availability:

All data generated or analyzed during this study are included in this published article.

Conflicts of interest:

Authors declare that they have no conflict of interest.




Figure 3: Molecular dynamics analyses for all backbone atoms for the PDGFR α /Luteolin complex over 100 ns simulations, with Avapritinib as a control: (a) RMSD, (b) RMSF, (c) Protein-Ligand Contacts and (d) Interaction Tendencies.




Figure 4: Molecular dynamics analyses for all backbone atoms for the c-Kit/Luteolin complex over 100 ns simulations, with Sunitinib as a control: (a) RMSD, (b) RMSF, (c) Protein-Ligand Contacts and (d) Interaction Tendencies.

References:

- [1] Corless CL *et al.* *Nat Rev Cancer*. 2011 **11**:865. [PMID: 22089421].
- [2] Hirota S *et al.* *Science*. 1998 **279**:577. [PMID: 9438854].
- [3] Heinrich MC *et al.* *J Clin Oncol*. 2006 **24**:4764. [PMID: 16954519].
- [4] Demetri GD *et al.* *N Engl J Med*. 2002 **347**:472. [PMID: 12181401].
- [5] Demetri GD *et al.* *Lancet*. 2013 **381**:295. [PMID: 23177515].
- [6] Cragg GM, Newman DJ. *J Ethnopharmacol*. 2005 **100**:72. [PMID: 16009521].
- [7] Alyamia MH *et al.* *RSC Adv*. 2023 **13**:26213. [DOI: 10.1039/D3RA05116A].
- [8] Saad B, Azaizeh H, Said O. *Evid Based Complement Alternat Med*. 2005;**2**:475. [PMID: 16322804].
- [9] Safe S *et al.* *Toxicol Res*. 2021 **37**:147. [DOI: 10.1007/s43188-020-00080-z].
- [10] López-Lázaro M. *Curr Med Chem Anticancer Agents*. 2002 **2**:691. [PMID: 12678721].
- [11] Wang Y, Zhang Q. *Cancer Biol Ther*. 2013;**14**:241. [PMID: 23370310].
- [12] Zhou Y *et al.* *Molecules*. 2024 **29**:2623. [DOI: 10.3390/molecules29112623].
- [13] Lü S, Wang J. *J Hematol Oncol*. 2014 **7**:2. [DOI: 10.1186/1756-8722-7-2].

- [14] Trott O, Olson AJ. *J Comput Chem*. 2010;**31**:455. [PMID: 19499576].
- [15] Eberhardt J *et al.* *J Chem Inf Model*. 2021 **61**:3891. [PMID: 34278794].
- [16] UniProt Consortium. *Nucleic Acids Res*. 2019;**47**. [PMID: 30395287].
- [17] El Yadini A *et al.* *Molecules*. 2023 **28**:1708. [PMID: 36838696].
- [18] Starosyla SA *et al.* *Struct Chem*. 2023 **34**:1157. [DOI: 10.1007/s11224-022-02075-y].
- [19] Daina A, Michielin O, Zoete V. *Sci Rep*. 2017;**7**:42717. [PMID: 28256516].
- [20] Bowers KJ *et al.* *SC '06: Proceedings of the 2006 ACM/IEEE Conference on Supercomputing*. 2006:43. [DOI: 10.1109/SC.2006.54].
- [21] Jorgensen WL *et al.* *J Chem Phys*. 1983 **79**:926. [DOI: 10.1063/1.445869].
- [22] Ryckaert JP *et al.* *J Comput Phys*. 1977 **23**:327. [DOI: 10.1016/0021-9991(77)90098-5].
- [23] Darden T *et al.* *J Chem Phys*. 1993 **98**:10089. [DOI: 10.1063/1.464397].
-